Archive · 8 Dec 2025
Biocon to Fully Acquire Biologics Subsidiary
Biocon, a big biopharmaceutical company, wants to fully own its subsidiary, Biocon Biologics Limited (BBL).
Right now, other companies like Viatris, Serum Institute, Tata Capital, and Activ Pine own small parts of BBL.
Biocon plans to buy these parts using a mix of shares and cash.
To get the cash, Biocon will borrow money in the short term and then raise more money later.
This move is expected to make Biocon's structure simpler and give it more control over its biologics business.
People who invest in Biocon's stock are watching closely to see how this news affects the stock price.
The stock has been going down a bit, but some experts think it's a good deal and the stock will go up in the future.
Biocon plans to fully merge Biocon Biologics Limited (BBL) into the parent company by acquiring the remaining 23.3% minority stake.
The company will acquire 40,55,86,862 shares of BBL to own 100% of its biologics arm, valued at $5.5 billion.
Biocon will use a mix of share swap (171.3 million Biocon equity shares worth $773 million) and cash payment ($400 million) to buy out stakeholders.
To fund the cash part of the deal, Biocon plans to raise up to Rs 4,500 crore through various methods, including a qualified institutional placement.
Biocon shares declined 2.01% to ₹384.75 on the NSE by early afternoon Monday, despite positive ratings from multiple brokerages.
- Who
- Biocon, Biocon Biologics Limited (BBL), Viatris, Serum Institute Life Sciences, Tata Capital Growth Fund II, Activ Pine LLP
- What
- Biocon is merging BBL into the parent company by acquiring minority stakes
- When
- The transaction is expected to complete by March 31, 2026, pending regulatory and shareholder approvals
- Where
- Mumbai, India
- Why
- To simplify company structure, strengthen control over the biologics business, and eliminate the holding company discount
- Company
- Biocon
- Subsidiary
- Biocon Biologics Limited (BBL)
- Minority Stakeholders
- Viatris, Serum Institute Life Sciences, Tata Capital Growth Fund II, Activ Pine LLP
- Shares to be Acquired
- 40,55,86,862
- Funding Amount
- Up to Rs 4,500 crore
- Short-term Funding
- Commercial papers worth up to Rs 1,800 crore
- Stock Price
- Rs 384.75 per share (as of early afternoon Monday)
- Year-to-Date Returns
- 6.30%
- Biocon Equity Shares Issued
- 171.3 million
- Expected Completion Date
- March 31, 2026
